These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 10975542)

  • 21. Imaging end points for monitoring neuroprotection in Parkinson's disease.
    Brooks DJ
    Ann Neurol; 2003; 53 Suppl 3():S110-8; discussion S118-9. PubMed ID: 12666103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Parkinson's disease--new horizons].
    Bötzel K
    MMW Fortschr Med; 2004 Mar; 146(10):21-3. PubMed ID: 15347072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease. Diagnosis and the initiation of therapy.
    Bhat V; Weiner WJ
    Minerva Med; 2005 Jun; 96(3):145-54. PubMed ID: 16175158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.
    Hälbig TD; Tse W; Olanow CW
    Neurol Clin; 2004 Oct; 22(3 Suppl):S1-S17. PubMed ID: 15501359
    [No Abstract]   [Full Text] [Related]  

  • 25. Levodopa--toxic or neuroprotective?
    Weiner WJ
    Nat Clin Pract Neurol; 2006 Oct; 2(10):518-9. PubMed ID: 16990820
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment challenges in early stage Parkinson's disease.
    Tetrud J
    Neurol Clin; 2004 Oct; 22(3 Suppl):S19-33. PubMed ID: 15501364
    [No Abstract]   [Full Text] [Related]  

  • 27. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
    Schapira AH
    Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotection and antiepileptogenesis: where are we now?
    Dichter MA; Cole AJ
    Neurology; 2002 Nov; 59(9 Suppl 5):S36-8. PubMed ID: 12428031
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiepileptic drugs to prevent neural degeneration associated with epilepsy: assessing the prospects for neuroprotection.
    Sutula T
    Epilepsy Res; 2002 Jun; 50(1-2):125-9. PubMed ID: 12151123
    [No Abstract]   [Full Text] [Related]  

  • 30. Estrogen and SERM neuroprotection in animal models of Parkinson's disease.
    Morissette M; Al Sweidi S; Callier S; Di Paolo T
    Mol Cell Endocrinol; 2008 Aug; 290(1-2):60-9. PubMed ID: 18515001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective trials: no longer a cautious optimism.
    Friedman JH
    Med Health R I; 2008 Jun; 91(6):158. PubMed ID: 18610798
    [No Abstract]   [Full Text] [Related]  

  • 32. Neuroprotection and antiepileptogenesis: overview, definitions, and context.
    Cole AJ; Dichter M
    Neurology; 2002 Nov; 59(9 Suppl 5):S1-2. PubMed ID: 12428024
    [No Abstract]   [Full Text] [Related]  

  • 33. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
    Youdim MB; Geldenhuys WJ; Van der Schyf CJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S281-91. PubMed ID: 18267251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neuroprotective activity of antiepileptic drugs].
    Czuczwar K; Czuczwar M; Cieszczyk J; Gawlik P; Luszczki JJ; Borowicz KK; Czuczwar SJ
    Przegl Lek; 2004; 61(11):1268-71. PubMed ID: 15727029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rasagiline -- is there a place for this drug in managing Parkinson's disease?
    Sharma JC
    Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281
    [No Abstract]   [Full Text] [Related]  

  • 36. Dopamine agonists modify the course of Parkinson disease.
    Stern MB
    Arch Neurol; 2004 Dec; 61(12):1969-71. PubMed ID: 15596624
    [No Abstract]   [Full Text] [Related]  

  • 37. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
    Wang LH; Johnson EM
    Neurology; 2008 Aug; 71(6):462; author reply 462-3. PubMed ID: 18678833
    [No Abstract]   [Full Text] [Related]  

  • 38. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.
    Pollard JR
    Curr Opin Investig Drugs; 2008 Jan; 9(1):101-7. PubMed ID: 18183537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interest in predictive testing for Parkinson's disease: impact of neuroprotective therapy.
    Dahodwala N; Connolly J; Farmer J; Stern MB; Jennings D; Siderowf A
    Parkinsonism Relat Disord; 2007 Dec; 13(8):495-9. PubMed ID: 17449316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.